how many people are taking glp 1 Consumers GLP-1s for Weight Loss, Current or Discontinued, Drive Lasting Changes in Retail, Per New Acosta Group Study GLP-1 Survey: 37.5% of People

or Canada) take on more consumer behaviors for their health and wellbeing, they are seeking care across sites beyond clinics and doctors offices notably online via telehealth and ecommerce channels as well as retail health environments like medi-spas or nutrition shops

Glucagon-like peptide1 receptor agonists (GLP-1RAs) have emerged as a transformative class of therapies initially developed for glycemic control in type2 diabetes mellitus

for Half the price

Tirzepatide, a dual GLP-1/GIP receptor agonist has been approved for glycaemic control in type 2 diabetes as well as for obesity management leading in up to 22.5% WL in phase 3 obesity trials

When GLP-1 receptor agonists (GLP-1RAs) were first approved over a decade ago, their primary indication was simple: help people with Type 2 diabetes manage their blood sugar

While oral formulations offer the convenience of a pill compared to traditional injections, this shift also raises important compliance considerations